Summary
This prediction ended on 19.03.18 with a price of €14.55. The BUY prediction by melinda for GSK plc closed nearly unchanged. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| GSK plc | -0.436% | -0.436% | 25.951% | 23.377% |
| iShares Core DAX® | 0.650% | 3.212% | 21.634% | 71.886% |
| iShares Nasdaq 100 | 1.650% | 0.322% | 5.422% | 113.046% |
| iShares Nikkei 225® | 1.232% | 1.549% | 15.333% | 47.267% |
| iShares S&P 500 | 1.413% | 0.282% | 3.125% | 68.687% |
According to melinda what are the pros and cons of GSK plc for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Cons
Comments by melinda for this prediction
In the thread GlaxoSmithKline plc diskutieren
Pharmazeutische SecteurProduits Agenda 25/04 Ergebnisse Veröffentlichung
GSK stellt fest , dass ViiV Healthcare verkündet positive Daten Dolutegravir
5. März (Reuters) - Glaxosmithkline Plc :: GLAXOSMITHKLINE PLC - ViiV Healthcare KÜNDIGT NEUE DATEN ZUR BEHANDLUNG VON MENSCHEN POSITIVE Dolutegravir mit HIV-Infizierte mit TUBERCULOSIS.GLAXOSMITHKLINE CO PLC - Dolutegravir WANN 50mg zweimal täglich zu MIT NUCLEOSID DOUBLE REVERSE.